array(40) {
  [0]=>
  string(4) "1563"
  ["article_id"]=>
  string(4) "1563"
  [1]=>
  string(124) "Epizyme Announces Registration Path for Tazemetostat for Follicular Lymphoma and Provides Pipeline Updates and 2019 Guidance"
  ["article_title"]=>
  string(124) "Epizyme Announces Registration Path for Tazemetostat for Follicular Lymphoma and Provides Pipeline Updates and 2019 Guidance"
  [2]=>
  string(150) "CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 4, 2019-- Epizyme, Inc. (Nasdaq: EPZM), a clinical-stage company developing novel epigenetic therapies, today "
  ["short_description"]=>
  string(150) "CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 4, 2019-- Epizyme, Inc. (Nasdaq: EPZM), a clinical-stage company developing novel epigenetic therapies, today "
  [3]=>
  string(252) "CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 4, 2019-- Epizyme, Inc. (Nasdaq: EPZM), a clinical-stage company developing novel epigenetic therapies, today announced a comprehensive set of pipeline updates, including that the company has identified a path..."
  ["description"]=>
  string(252) "CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 4, 2019-- Epizyme, Inc. (Nasdaq: EPZM), a clinical-stage company developing novel epigenetic therapies, today announced a comprehensive set of pipeline updates, including that the company has identified a path..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(300) "https://www.drugs.com/clinical_trials/epizyme-announces-registration-path-tazemetostat-follicular-lymphoma-provides-pipeline-updates-2019-18050.html?utm_source=ddc&utm_medium=rss&utm_campaign=Epizyme+Announces+Registration+Path+for+Tazemetostat+for+Follicular+Lymphoma+and+Provides+Pipeline+Updates+a"
  ["blog_url"]=>
  string(300) "https://www.drugs.com/clinical_trials/epizyme-announces-registration-path-tazemetostat-follicular-lymphoma-provides-pipeline-updates-2019-18050.html?utm_source=ddc&utm_medium=rss&utm_campaign=Epizyme+Announces+Registration+Path+for+Tazemetostat+for+Follicular+Lymphoma+and+Provides+Pipeline+Updates+a"
  [15]=>
  string(19) "2019-01-05 05:01:47"
  ["add_date"]=>
  string(19) "2019-01-05 05:01:47"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-01-15 18:25:23"
  ["create_at"]=>
  string(19) "2019-01-15 18:25:23"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1539"
  ["article_id"]=>
  string(4) "1539"
  [1]=>
  string(146) "Nabriva Therapeutics Announces Acceptance of the New Drug Application for Intravenous Contepo to Treat Complicated Urinary Tract Infections by FDA"
  ["article_title"]=>
  string(146) "Nabriva Therapeutics Announces Acceptance of the New Drug Application for Intravenous Contepo to Treat Complicated Urinary Tract Infections by FDA"
  [2]=>
  string(150) "DUBLIN, Ireland, Jan. 04, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a clinical-stage biopharmaceutical company engaged in the "
  ["short_description"]=>
  string(150) "DUBLIN, Ireland, Jan. 04, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a clinical-stage biopharmaceutical company engaged in the "
  [3]=>
  string(252) "DUBLIN, Ireland, Jan. 04, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a clinical-stage biopharmaceutical company engaged in the research and development of innovative anti-infective agents to treat serious infections, announced..."
  ["description"]=>
  string(252) "DUBLIN, Ireland, Jan. 04, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a clinical-stage biopharmaceutical company engaged in the research and development of innovative anti-infective agents to treat serious infections, announced..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "9"
  ["rss_id"]=>
  string(1) "9"
  [14]=>
  string(235) "https://www.drugs.com/nda/contepo_190104.html?utm_source=ddc&utm_medium=rss&utm_campaign=Nabriva+Therapeutics+Announces+Acceptance+of+the+New+Drug+Application+for+Intravenous+Contepo+to+Treat+Complicated+Urinary+Tract+Infections+by+FDA"
  ["blog_url"]=>
  string(235) "https://www.drugs.com/nda/contepo_190104.html?utm_source=ddc&utm_medium=rss&utm_campaign=Nabriva+Therapeutics+Announces+Acceptance+of+the+New+Drug+Application+for+Intravenous+Contepo+to+Treat+Complicated+Urinary+Tract+Infections+by+FDA"
  [15]=>
  string(19) "2019-01-05 05:01:10"
  ["add_date"]=>
  string(19) "2019-01-05 05:01:10"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-01-15 18:25:20"
  ["create_at"]=>
  string(19) "2019-01-15 18:25:20"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2389"
  ["article_id"]=>
  string(4) "2389"
  [1]=>
  string(41) "New Standard for Biocompatibility Testing"
  ["article_title"]=>
  string(41) "New Standard for Biocompatibility Testing"
  [2]=>
  string(153) "&#nl        On the assembly line, every medical device is thoroughly checked for quality and functionality. Are all the parts present? Is the needle shar"
  ["short_description"]=>
  string(153) "&#nl        On the assembly line, every medical device is thoroughly checked for quality and functionality. Are all the parts present? Is the needle shar"
  [3]=>
  string(324) "&#nl        On the assembly line, every medical device is thoroughly checked for quality and functionality. Are all the parts present? Is the needle sharp? Does the device leak? Does air flow where, when and how it’s supposed to? Do triggers and control knobs function correctly? Does the touch screen work?&#nl      "
  ["description"]=>
  string(324) "&#nl        On the assembly line, every medical device is thoroughly checked for quality and functionality. Are all the parts present? Is the needle sharp? Does the device leak? Does air flow where, when and how it’s supposed to? Do triggers and control knobs function correctly? Does the touch screen work?&#nl      "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "99"
  ["rss_id"]=>
  string(2) "99"
  [14]=>
  string(84) "https://www.assemblymag.com/articles/94616-new-standard-for-biocompatibility-testing"
  ["blog_url"]=>
  string(84) "https://www.assemblymag.com/articles/94616-new-standard-for-biocompatibility-testing"
  [15]=>
  string(19) "2019-01-05 03:20:00"
  ["add_date"]=>
  string(19) "2019-01-05 03:20:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:42:22"
  ["create_at"]=>
  string(19) "2019-05-09 16:42:22"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2390"
  ["article_id"]=>
  string(4) "2390"
  [1]=>
  string(45) "Automation helps medical device maker compete"
  ["article_title"]=>
  string(45) "Automation helps medical device maker compete"
  [2]=>
  string(153) "&#nl        Merit Medical Systems Inc. is a leading manufacturer of disposable medical devices used in interventional, diagnostic and therapeutic procedu"
  ["short_description"]=>
  string(153) "&#nl        Merit Medical Systems Inc. is a leading manufacturer of disposable medical devices used in interventional, diagnostic and therapeutic procedu"
  [3]=>
  string(245) "&#nl        Merit Medical Systems Inc. is a leading manufacturer of disposable medical devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care and endoscopy.&#nl      "
  ["description"]=>
  string(245) "&#nl        Merit Medical Systems Inc. is a leading manufacturer of disposable medical devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care and endoscopy.&#nl      "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "99"
  ["rss_id"]=>
  string(2) "99"
  [14]=>
  string(88) "https://www.assemblymag.com/articles/94615-automation-helps-medical-device-maker-compete"
  ["blog_url"]=>
  string(88) "https://www.assemblymag.com/articles/94615-automation-helps-medical-device-maker-compete"
  [15]=>
  string(19) "2019-01-05 03:14:00"
  ["add_date"]=>
  string(19) "2019-01-05 03:14:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:42:22"
  ["create_at"]=>
  string(19) "2019-05-09 16:42:22"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1564"
  ["article_id"]=>
  string(4) "1564"
  [1]=>
  string(131) "Verrica Achieves Positive Topline Results from Two Pivotal Phase 3 Clinical Trials of VP-102 in Patients with Molluscum Contagiosum"
  ["article_title"]=>
  string(131) "Verrica Achieves Positive Topline Results from Two Pivotal Phase 3 Clinical Trials of VP-102 in Patients with Molluscum Contagiosum"
  [2]=>
  string(150) "WEST CHESTER, Pa., Jan. 03, 2019 (GLOBE NEWSWIRE) --  Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a pharmaceutical company focused on "
  ["short_description"]=>
  string(150) "WEST CHESTER, Pa., Jan. 03, 2019 (GLOBE NEWSWIRE) --  Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a pharmaceutical company focused on "
  [3]=>
  string(252) "WEST CHESTER, Pa., Jan. 03, 2019 (GLOBE NEWSWIRE) --  Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a pharmaceutical company focused on identifying, developing and commercializing innovative pharmaceutical products for the treatment of..."
  ["description"]=>
  string(252) "WEST CHESTER, Pa., Jan. 03, 2019 (GLOBE NEWSWIRE) --  Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a pharmaceutical company focused on identifying, developing and commercializing innovative pharmaceutical products for the treatment of..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(300) "https://www.drugs.com/clinical_trials/verrica-achieves-positive-topline-results-two-pivotal-phase-3-clinical-trials-vp-102-patients-18049.html?utm_source=ddc&utm_medium=rss&utm_campaign=Verrica+Achieves+Positive+Topline+Results+from+Two+Pivotal+Phase+3+Clinical+Trials+of+VP-102+in+Patients+with+Moll"
  ["blog_url"]=>
  string(300) "https://www.drugs.com/clinical_trials/verrica-achieves-positive-topline-results-two-pivotal-phase-3-clinical-trials-vp-102-patients-18049.html?utm_source=ddc&utm_medium=rss&utm_campaign=Verrica+Achieves+Positive+Topline+Results+from+Two+Pivotal+Phase+3+Clinical+Trials+of+VP-102+in+Patients+with+Moll"
  [15]=>
  string(19) "2019-01-04 05:01:47"
  ["add_date"]=>
  string(19) "2019-01-04 05:01:47"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-01-15 18:25:23"
  ["create_at"]=>
  string(19) "2019-01-15 18:25:23"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1565"
  ["article_id"]=>
  string(4) "1565"
  [1]=>
  string(83) "Kiniksa Announces Active U.S. Investigational New Drug Application for Mavrilimumab"
  ["article_title"]=>
  string(83) "Kiniksa Announces Active U.S. Investigational New Drug Application for Mavrilimumab"
  [2]=>
  string(150) "HAMILTON, Bermuda, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company"
  ["short_description"]=>
  string(150) "HAMILTON, Bermuda, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company"
  [3]=>
  string(250) "HAMILTON, Bermuda, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a pipeline of five product candidates across various stages of development, today announced..."
  ["description"]=>
  string(250) "HAMILTON, Bermuda, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a pipeline of five product candidates across various stages of development, today announced..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(249) "https://www.drugs.com/clinical_trials/kiniksa-announces-active-u-s-investigational-new-application-mavrilimumab-18048.html?utm_source=ddc&utm_medium=rss&utm_campaign=Kiniksa+Announces+Active+U.S.+Investigational+New+Drug+Application+for+Mavrilimumab"
  ["blog_url"]=>
  string(249) "https://www.drugs.com/clinical_trials/kiniksa-announces-active-u-s-investigational-new-application-mavrilimumab-18048.html?utm_source=ddc&utm_medium=rss&utm_campaign=Kiniksa+Announces+Active+U.S.+Investigational+New+Drug+Application+for+Mavrilimumab"
  [15]=>
  string(19) "2019-01-04 05:01:08"
  ["add_date"]=>
  string(19) "2019-01-04 05:01:08"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-01-15 18:25:23"
  ["create_at"]=>
  string(19) "2019-01-15 18:25:23"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1854"
  ["article_id"]=>
  string(4) "1854"
  [1]=>
  string(129) "ATAI Life Sciences acquires majority stake in Perception Neuroscience to develop arketamine therapy for neuropsychiatric diseases"
  ["article_title"]=>
  string(129) "ATAI Life Sciences acquires majority stake in Perception Neuroscience to develop arketamine therapy for neuropsychiatric diseases"
  [2]=>
  string(150) "Munich and New York, 03 January 2019 - ATAI Life Sciences AG has acquired a majority stake in New York based Perception Neuroscience, a biopharmaceuti"
  ["short_description"]=>
  string(150) "Munich and New York, 03 January 2019 - ATAI Life Sciences AG has acquired a majority stake in New York based Perception Neuroscience, a biopharmaceuti"
  [3]=>
  string(518) "Munich and New York, 03 January 2019 - ATAI Life Sciences AG has acquired a majority stake in New York based Perception Neuroscience, a biopharmaceutical company focused on developing innovative therapies in neuropsychiatry. Perception was founded by Jonathan Sporn, MD, and Jay Kranzler, MD, PhD, both of whom have held multiple senior R&D leadership roles in the pharmaceutical industry and will continue to be minority shareholders. The company has been advised by Bruce Leuchter from...&#nl&#nlSource: RealWire"
  ["description"]=>
  string(518) "Munich and New York, 03 January 2019 - ATAI Life Sciences AG has acquired a majority stake in New York based Perception Neuroscience, a biopharmaceutical company focused on developing innovative therapies in neuropsychiatry. Perception was founded by Jonathan Sporn, MD, and Jay Kranzler, MD, PhD, both of whom have held multiple senior R&D leadership roles in the pharmaceutical industry and will continue to be minority shareholders. The company has been advised by Bruce Leuchter from...&#nl&#nlSource: RealWire"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "64"
  ["rss_id"]=>
  string(2) "64"
  [14]=>
  string(102) "http://www.realwire.com/releases/ATAI-Life-Sciences-acquires-majority-stake-in-Perception-Neuroscience"
  ["blog_url"]=>
  string(102) "http://www.realwire.com/releases/ATAI-Life-Sciences-acquires-majority-stake-in-Perception-Neuroscience"
  [15]=>
  string(19) "2019-01-03 18:53:00"
  ["add_date"]=>
  string(19) "2019-01-03 18:53:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-04-22 13:42:54"
  ["create_at"]=>
  string(19) "2019-04-22 13:42:54"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "4552"
  ["article_id"]=>
  string(4) "4552"
  [1]=>
  string(29) "Annual European Dental Summit"
  ["article_title"]=>
  string(29) "Annual European Dental Summit"
  [2]=>
  string(150) "We are hosting the "Annual European Dental Summit "(Dental Summit 2019) along with external scientific association with the researches, acad"
  ["short_description"]=>
  string(150) "We are hosting the "Annual European Dental Summit "(Dental Summit 2019) along with external scientific association with the researches, acad"
  [3]=>
  string(532) "We are hosting the "Annual European Dental Summit "(Dental Summit 2019) along with external scientific association with the researches, academicians, and Students around the globe, scheduled on September 20-21, 2019 at London.UK&#nl&#nlThe Theme of the conference is “Tomorrows Dentistry Today” which works with an objective to encourage young minds and their research abilities by providing an opportunity to meet the experts in the field of Dental & Oral Care. It includes Keynote Presentations, W..."
  ["description"]=>
  string(532) "We are hosting the "Annual European Dental Summit "(Dental Summit 2019) along with external scientific association with the researches, academicians, and Students around the globe, scheduled on September 20-21, 2019 at London.UK&#nl&#nlThe Theme of the conference is “Tomorrows Dentistry Today” which works with an objective to encourage young minds and their research abilities by providing an opportunity to meet the experts in the field of Dental & Oral Care. It includes Keynote Presentations, W..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "3"
  ["category"]=>
  string(1) "3"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "58"
  ["rss_id"]=>
  string(2) "58"
  [14]=>
  string(63) "https://www.pharmiweb.com/event/annual-european-dental-summit-1"
  ["blog_url"]=>
  string(63) "https://www.pharmiweb.com/event/annual-european-dental-summit-1"
  [15]=>
  string(19) "2019-01-03 12:09:13"
  ["add_date"]=>
  string(19) "2019-01-03 12:09:13"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-09-14 14:32:21"
  ["create_at"]=>
  string(19) "2019-09-14 14:32:21"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "5315"
  ["article_id"]=>
  string(4) "5315"
  [1]=>
  string(61) "BIT's 4th Annual World Congress of Digestive Disease-2019"
  ["article_title"]=>
  string(61) "BIT's 4th Annual World Congress of Digestive Disease-2019"
  [2]=>
  string(150) "The Annual World Congress of Digestive Disease (WCDD), initiated from 2015, has been successfully organized in Nanjing, China, Fukuoka, Japan and Rome"
  ["short_description"]=>
  string(150) "The Annual World Congress of Digestive Disease (WCDD), initiated from 2015, has been successfully organized in Nanjing, China, Fukuoka, Japan and Rome"
  [3]=>
  string(507) "The Annual World Congress of Digestive Disease (WCDD), initiated from 2015, has been successfully organized in Nanjing, China, Fukuoka, Japan and Rome, Italy in the previous three conferences. We are so proud to announce that BIT's 4th Annual World Congress of Digestive Disease (WCDD-2019) will be held on Nov. 9-11, 2019 in the beautiful city of Kunming, China.&#nlWCDD is an international event focusing on the field of digestive disease, and it provides new insight into clinical research and the..."
  ["description"]=>
  string(507) "The Annual World Congress of Digestive Disease (WCDD), initiated from 2015, has been successfully organized in Nanjing, China, Fukuoka, Japan and Rome, Italy in the previous three conferences. We are so proud to announce that BIT's 4th Annual World Congress of Digestive Disease (WCDD-2019) will be held on Nov. 9-11, 2019 in the beautiful city of Kunming, China.&#nlWCDD is an international event focusing on the field of digestive disease, and it provides new insight into clinical research and the..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "3"
  ["category"]=>
  string(1) "3"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "58"
  ["rss_id"]=>
  string(2) "58"
  [14]=>
  string(88) "https://www.pharmiweb.com/event/bits-4th-annual-world-congress-of-digestive-disease-2019"
  ["blog_url"]=>
  string(88) "https://www.pharmiweb.com/event/bits-4th-annual-world-congress-of-digestive-disease-2019"
  [15]=>
  string(19) "2019-01-03 10:46:44"
  ["add_date"]=>
  string(19) "2019-01-03 10:46:44"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-10-31 15:50:28"
  ["create_at"]=>
  string(19) "2019-10-31 15:50:28"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1566"
  ["article_id"]=>
  string(4) "1566"
  [1]=>
  string(124) "Catabasis Pharmaceuticals Phase 3 PolarisDMD Clinical Trial For Edasalonexent In Duchenne Muscular Dystrophy Progress Update"
  ["article_title"]=>
  string(124) "Catabasis Pharmaceuticals Phase 3 PolarisDMD Clinical Trial For Edasalonexent In Duchenne Muscular Dystrophy Progress Update"
  [2]=>
  string(150) "CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 3, 2019-- Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today sha"
  ["short_description"]=>
  string(150) "CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 3, 2019-- Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today sha"
  [3]=>
  string(251) "CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 3, 2019-- Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today shared an update on clinical trial sites in the United States and recent international clinical trial..."
  ["description"]=>
  string(251) "CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 3, 2019-- Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today shared an update on clinical trial sites in the United States and recent international clinical trial..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(300) "https://www.drugs.com/clinical_trials/catabasis-pharmaceuticals-phase-3-polarisdmd-clinical-trial-edasalonexent-duchenne-muscular-18046.html?utm_source=ddc&utm_medium=rss&utm_campaign=Catabasis+Pharmaceuticals+Phase+3+PolarisDMD+Clinical+Trial+For+Edasalonexent+In+Duchenne+Muscular+Dystrophy+Progres"
  ["blog_url"]=>
  string(300) "https://www.drugs.com/clinical_trials/catabasis-pharmaceuticals-phase-3-polarisdmd-clinical-trial-edasalonexent-duchenne-muscular-18046.html?utm_source=ddc&utm_medium=rss&utm_campaign=Catabasis+Pharmaceuticals+Phase+3+PolarisDMD+Clinical+Trial+For+Edasalonexent+In+Duchenne+Muscular+Dystrophy+Progres"
  [15]=>
  string(19) "2019-01-03 08:01:06"
  ["add_date"]=>
  string(19) "2019-01-03 08:01:06"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-01-15 18:25:23"
  ["create_at"]=>
  string(19) "2019-01-15 18:25:23"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1567"
  ["article_id"]=>
  string(4) "1567"
  [1]=>
  string(56) "BioCryst Initiates Phase 1 Clinical Trial of Galidesivir"
  ["article_title"]=>
  string(56) "BioCryst Initiates Phase 1 Clinical Trial of Galidesivir"
  [2]=>
  string(150) "RESEARCH TRIANGLE PARK, N.C., Jan. 02, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced the dosing of the first s"
  ["short_description"]=>
  string(150) "RESEARCH TRIANGLE PARK, N.C., Jan. 02, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced the dosing of the first s"
  [3]=>
  string(247) "RESEARCH TRIANGLE PARK, N.C., Jan. 02, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced the dosing of the first subject in a randomized, placebo-controlled phase 1 clinical trial to evaluate intravenous (IV)..."
  ["description"]=>
  string(247) "RESEARCH TRIANGLE PARK, N.C., Jan. 02, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced the dosing of the first subject in a randomized, placebo-controlled phase 1 clinical trial to evaluate intravenous (IV)..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(202) "https://www.drugs.com/clinical_trials/biocryst-initiates-phase-1-clinical-trial-galidesivir-18044.html?utm_source=ddc&utm_medium=rss&utm_campaign=BioCryst+Initiates+Phase+1+Clinical+Trial+of+Galidesivir"
  ["blog_url"]=>
  string(202) "https://www.drugs.com/clinical_trials/biocryst-initiates-phase-1-clinical-trial-galidesivir-18044.html?utm_source=ddc&utm_medium=rss&utm_campaign=BioCryst+Initiates+Phase+1+Clinical+Trial+of+Galidesivir"
  [15]=>
  string(19) "2019-01-02 08:01:19"
  ["add_date"]=>
  string(19) "2019-01-02 08:01:19"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-01-15 18:25:23"
  ["create_at"]=>
  string(19) "2019-01-15 18:25:23"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "4869"
  ["article_id"]=>
  string(4) "4869"
  [1]=>
  string(47) "International Conference on Textile Engineering"
  ["article_title"]=>
  string(47) "International Conference on Textile Engineering"
  [2]=>
  string(150) "International Conference on Textile Engineering (TextileEngg-2019), which will be held during October 21-22, 2019 Bangkok, Thailand is now an establis"
  ["short_description"]=>
  string(150) "International Conference on Textile Engineering (TextileEngg-2019), which will be held during October 21-22, 2019 Bangkok, Thailand is now an establis"
  [3]=>
  string(479) "International Conference on Textile Engineering (TextileEngg-2019), which will be held during October 21-22, 2019 Bangkok, Thailand is now an established event, attracting global participant’s intent on sharing, exchanging and exploring new avenues of TextileEngg-2019 and textile technology deals with the application of scientific and engineering principles to the design and control of all aspects of fiber, textile, and apparel processes, products, and machinery. &#nl"
  ["description"]=>
  string(479) "International Conference on Textile Engineering (TextileEngg-2019), which will be held during October 21-22, 2019 Bangkok, Thailand is now an established event, attracting global participant’s intent on sharing, exchanging and exploring new avenues of TextileEngg-2019 and textile technology deals with the application of scientific and engineering principles to the design and control of all aspects of fiber, textile, and apparel processes, products, and machinery. &#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "3"
  ["category"]=>
  string(1) "3"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "58"
  ["rss_id"]=>
  string(2) "58"
  [14]=>
  string(79) "https://www.pharmiweb.com/event/international-conference-on-textile-engineering"
  ["blog_url"]=>
  string(79) "https://www.pharmiweb.com/event/international-conference-on-textile-engineering"
  [15]=>
  string(19) "2018-12-27 20:04:16"
  ["add_date"]=>
  string(19) "2018-12-27 20:04:16"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-09-27 14:12:08"
  ["create_at"]=>
  string(19) "2019-09-27 14:12:08"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}